MRK vs XOM: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
VS
Exxon Mobil Corporation · Energy
$137.81
-45.0% upside to fair value
Grade C
QuantHub Verdict
MRK has more upside to fair value
(-12.1%).
XOM trades at a lower forward P/E
(22.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
XOM |
| Current Price |
$113.87 |
$137.81 |
| Fair Value Estimate |
$100.14 |
$75.80 |
| Upside to Fair Value |
-12.1%
|
-45.0%
|
| Market Cap |
$281.2B |
$571.2B |
| Forward P/E |
32.0x
|
22.8x
|
| EV / EBITDA |
17.3x
|
10.1x
|
| Price / Sales |
4.3x
|
1.8x
|
| Price / FCF |
19.9x
|
30.4x
|
| Revenue Growth YoY |
+4.3%
|
+2.6%
|
| Gross Margin |
75.9%
|
25.5%
|
| Operating Margin |
27.6%
|
9.0%
|
| Return on Equity |
17.9%
|
9.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.02%
|
3.29%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Exxon Mobil Corporation is a leading integrated oil and gas company with a durable competitive moat based on its scale, integration, advantaged long-life resources, proprietary technology, and irreplaceable infrastructure. The company is led by a long-tenured management team with a strong capital allocation track record focused on dividends and buybacks. Despite these strengths, Exxon is currentl…
Accumulation Zones
| Metric |
MRK |
XOM |
| Zone Low |
$75.11 |
$56.85 |
| Zone High |
$85.12 |
$64.43 |
| In Buy Zone? |
No
|
No
|